MGMT and PTEN as potential prognostic markers in breast cancer

Experimental and Molecular Pathology

Volumn 92, Issue 1, 2012, Pages 20-26

  Neto, Julio Cirullo ^a   Ikoma, Mariana Mari ^a   Carvalho, Katia Cândido ^b   Vassallo, José ^a   De Brot, Marina ^c   Gobbi, Helenice ^c   Soares, Fernando Augusto ^a   Rocha, Rafael Malagoli ^a  

^a A C CAMARGO CANCER CENTER   (Brazil)

^b UNIVERSITY OF SÃO PAULO   (Brazil)

^c FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

Author keywords

Basal like carcinomas; Breast cancer; MGMT; Prognosis; PTEN

Indexed keywords

CYTOKERATIN 14; CYTOKERATIN 5; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; MONOCLONAL ANTIBODY KI 67; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROGESTERONE RECEPTOR; PROTEIN P53; PROTEIN P63; UVOMORULIN;

ARTICLE; BREAST CANCER; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE DELETION; GENE EXPRESSION; GENETIC MARKER; HOMOZYGOSITY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; PHENOTYPE; PROGNOSIS; PROTEIN ANALYSIS; PROTEIN FUNCTION; PROTEIN LOCALIZATION; REAL TIME POLYMERASE CHAIN REACTION; TISSUE MICROARRAY;

ANTIBODIES; BRAZIL; BREAST NEOPLASMS; CARCINOMA; DNA MODIFICATION METHYLASES; DNA REPAIR ENZYMES; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; PHENOTYPE; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PTEN PHOSPHOHYDROLASE; REAL-TIME POLYMERASE CHAIN REACTION; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; RNA, MESSENGER; TISSUE ARRAY ANALYSIS; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEINS;

EID: 80155187122     PISSN: 00144800     EISSN: 10960945     Source Type: Journal    
DOI: 10.1016/j.yexmp.2011.09.019     Document Type: Article

References (29)

1. Allred D.C., Harvey J.M., Berardo M., et al. Prognostic and predictive factors in breast cancer by immunohistochemical analysis. Modern Pathology 1998, 11:155-168.
2. Bobola M.S., Blank A., Berger M.S., et al. Lack of the DNA repair proteins O6-methylguanine-DNA methyltransferase in histologically normal brain adjacent to primary human brain tumors. Proceedings of the National Academy of Sciences of the United States of America 1996, 93:6941-6946.
3. Danam R.P., Qian X.C., Howell S.R., et al. Methylation of selected CpGs in the human O6-methylguanine-DNA methyltransferase promoter region as a marker of gene silencing. Molecular Carcinogenesis 1999, 24:85-89.
4. Depowski P.L., Rosenthal S.I., Ross J.S. Loss of expression of the PTEN gene protein product is associated with poor outcome in breast cancer. Modern Pathology 2001, 14:672-676.
5. Gerson S.L. MGMT: its role in cancer aetiology and cancer therapeutics. Nature Reviews. Cancer 2004, 4:296-307.
6. Helleday T., Petermann E., Lundin C., et al. DNA repair pathways as targets for cancer therapy. Nature Reviews. Cancer 2008, 8:193-204.
7. Jacinto F.V., Esteller M. MGMT hypermethylation: a prognostic foe, a predictive friend. DNA Repair 2007, 6:1155-1160.
8. Kaina B., Christmann M., Naumann S., et al. MGMT: key note in the battle against genotoxicity, carcinogenicity and apoptosis induced by alkylating agents. DNA Repair 2007, 6:1079-1099.
9. Liu L., Gerson S.L. Targeted modulation of MGMT. clinical implications. Clinical Cancer Research 2006, 12:328-331.
10. Matsukura S., Miyazaki K., Yakushiji H., et al. Expression and prognostic significance of O6-methylguanine-DNA methyltransferase in hepatocellular, gastric, and breast cancers. Annals of Surgical Oncology 2001, 8:807-816.
11. Millikan R.C., Newman B., Tse C.K., et al. Epidemiology of basal-like breast cancer. Breast Cancer Research and Treatment 2008, 109:123-139.
12. Munot K., Bell S.M., Lane S., et al. Pattern of expression of genes linked to epigenetic silencing in human breast cancer. Human Pathology 2006, 37:989-999.
13. Osanai T., Takagi Y., Toriya Y., et al. Inverse correlation between the expression of O6-methylguanine-DNA methyl transferase (MGMT) and p53 in breast cancer. Japanese Journal of Clinical Oncology 2005, 35:121-125.
14. Pegg A.E. Mammalian O6-alkylguanine-DNA alkyltransferase: regulation and importance in response to alkylating carcinogenic and therapeutic agents. Cancer Research 1990, 50:6119-6129.
15. Pegg A.E., Dolan M.E., Moschel R.C. Structure, function, and inhibition of O6-alkylguanine-DNA alkyltransferase. Progress in Nucleic Acid Research and Molecular Biology 1995, 51:167-223.
16. Pegg A.E., Fang Q., Loktionova N.A. Human variants of O6-alkylguanine-DNA alkyltransferase. DNA Repair 2007, 6:1071-1078.
17. Perez-Tenorio G., Stal O. Activation of AKT/PKB in breast cancer predicts a worse outcome among endocrine treated patients. British Journal of Cancer 2002, 86:540-545.
18. Perou C.M., Sørlie T., Eisen M.B., et al. Molecular portraits of human breast tumours. Nature 2000, 406:747-752.
19. Pieper R.O. Understanding and manipulating O6-methylguanine-DNA methyltransferase expression. Pharmacology & Therapeutics 1997, 74:285-297.
20. Sabharwal A., Middleton M.R. Exploiting the role of o6-methylguanine-DNA-methyltransferase (MGMT) in cancer therapy. Current Opinion in Pharmacology 2006, 6:355-363.
21. Salmena L., Carracedo A., Pandolfi P.P. Tenets of PTEN tumor suppression. Cell 2008, 133:403-414.
22. Sawhney M., Rohatgi N., Kaur J., et al. MGMT expression in oral precancerous and cancerous lesions: correlation with progression, nodal metastasis and poor prognosis. Oral Oncology 2007, 43:515-522.
23. Sharma S., Salehi F., Scheithauer B.W., et al. Role of MGMT in tumor development, progression, diagnosis, treatment and prognosis. Anticancer Research 2009, 29:3759-3768.
24. Shen W.H., Balajee A.S., Wang J., et al. Essential role for nuclear PTEN in maintaining chromosomal integrity. Cell 2007, 128:157-170.
25. Shoman N., Klassen S., McFadden A., et al. Reduced PTEN expression predicts relapse in patients with breast carcinoma treated by tamoxifen. Modern Pathology 2004, 18:250-259.
26. Soejima H., Zhao W., Mukai T. Epigenetic silencing of the MGMT gene in cancer. Biochemistry and Cell Biology 2005, 83:429-437.
27. Sorlie T., Perou C.M., Tibshirani R., et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proceedings of the National Academy of Sciences 2001, 98:10869-10874.
28. Tsutsui S., Inoue H., Yasuda K., et al. Reduced expression of PTEN protein and its prognostic implications in invasive ductal carcinoma of the breast. Oncology 2005, 68:398-404.
29. Wolff A.C., Hammond M.E., Schwartz J.N., et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. Journal of Clinical Oncology 2007, 25:118-145.